Enhancement of Phthalocyanine Mediated Photodynamic Therapy by Catechin on Lung Cancer Cells

Giftson J. Senapathy, Blassan P. George and Heidi Abrahamse *
Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, 2028 Doornfontein, South Africa; giftsons@uj.ac.za (G.J.S.); blassang@uj.ac.za (B.P.G.)
* Correspondence: habrahamse@uj.ac.za; Tel.: +27-11-559-6550

Abstract: Worldwide, lung cancer remains one of the leading cancers with increasing mortality rates. Though chemotherapy for lung cancer is effective, it is always accompanied by unavoidable and grave side effects. Photodynamic therapy (PDT), using novel photosensitizers, is an advanced treatment method with relatively few side effects. Plant products are emerging as potent photosensitizers (PSs). The dose-dependent effect of Catechin (CA) (20–100 µM) on cellular morphological changes, cell viability, cytotoxicity, proliferation, DNA damage and apoptosis were studied on A549 adenocarcinoma alveolar basal epithelial cells. The effect of CA, along with Zinc phthalocyanine PS at 680 nm and 5 J/cm² fluency was also studied. As the doses of CA increased, the results showed a pattern of increased cytotoxicity, accompanied by decreased cell viability and proliferation in A549 cells. Also, at 52 µM (IC₅₀), CA in combination with PS significantly increased the cytotoxicity, DNA damage, and apoptosis, as compared to control and PS alone, treated cells in PDT experiments. These findings leave a possible thread that CA can be used in the application of phyto-photodynamic therapy of cancer in future.

Keywords: catechin; photodynamic therapy; lung cancer; natural product; dose-response; phytochemical; cancer treatment

1. Introduction

Cancer is a multi-factorial disease characterized by the uncontrolled growth of cells resulting in the formation of malignant tumors. Globally lung cancer leads all the other types of cancers in terms of its occurrence, severity, morbidity, and mortality rates [1]. It is estimated that lung cancer deaths may outnumber 3 million by 2035. Smoking, environmental pollution, and radiation are important causes of lung cancer. The usual treatment strategies, such as radiotherapy, surgery, and chemotherapy were not offering satisfactory results for lung cancer [2]. Systemic administration of chemotherapeutic drugs, minimal drug entry to the site of action, side effects of commonly used chemotherapeutic drugs to the extent of pausing the treatment till patient recovery were some of the notable disadvantages of lung cancer chemotherapy, making the practice less appealing. Non-surgical treatment strategies have evolved significantly in the recent decades and are employed in treating lung cancer. Therefore, a new alternative treatment that would address all or most of these issues would be an ideal cancer treatment method [3].

Photodynamic therapy (PDT), or phototherapy or non-ionizing radiation therapy introduced in 1970s, is one of the latest treatment strategies when compared to chemo and radiotherapy. Ever since its discovery, in the past few decades it was employed in the treatment of various malignant tumors including melanoma, breast, colon and lung cancers with less invasiveness [4]. Compared to other
conventional treatments like radiotherapy, surgery, and chemotherapy, it is more selective and relatively less toxic with less or no damage to normal cells. PDT is comparatively safe and minimally invasive [5]. Three individual components, namely the light source of appropriate wavelength, oxygen (O₂) and light-sensitive chemical agents known as photosensitizers are essential for PDT. PDT induces the activation of chemical photosensitizers by laser lights of specific wavelength to produce singlet oxygen (O₂*) and reactive oxygen species (ROS) that can harm the cell membranes and components resulting in necrosis and/or apoptosis. But the clinically available photosensitizers were accompanied with few disadvantages like minimal photosensitivity, phototoxicity, and less selectivity of tumors, which leads to the search for new compounds which have photosensitizing effects or which can modulate PDT [6,7].

A vast array of natural compounds has shown anticancer activities either separately or in blend with other therapies. Many phytochemicals, particularly flavonoids, have recently reported to have photosensitizing properties and hence, can act as natural photosensitizers in PDT [8].

Catechin or (+) Catechin hydrate (CA) (Figure 1) is a non-toxic and less expensive flavonoid present predominantly in green tea and other dietary products, plants, berry fruits (strawberry, raspberry, gooseberry, and blueberry), grapes, pineapples, kiwi, cocoa and beverages such as red wine and beer [9]. A green tea preparation (1 g tea leaves) has 30–40% of CAs in its 0.2–0.4 g of dry materials [10]. The term CA is originated from ‘catechu’, a tannic juice obtained from boiling the extracts of Mimosa catechu. CAs are powerful antioxidants, but besides this, they also can act as pro-oxidants. Research evidence has shown that they exhibit selective genotoxic and cytotoxic activities, particularly in cancer cells, including breast and cervical cancer cells, but not in normal cells [11]. Since CAs utilize the multiple targets of cancer treatment, they are found to be extremely useful to treat multidrug-resistant tumors [12]. They also affect the molecular mechanisms of angiogenesis, regulatory signals of cell death and other targets of cancer [13–16]. CAs are reported to have direct interaction with molecular pathways by binding to phospholipids and proteins. As a result, they modulate the enzymes and regulate cancer signaling pathways [17].

Figure 1. Chemical structure of catechin or (+) catechin hydrate.

Based on the above literature, the present study was designed to explore the dose-dependant anticancer effect of CA in A549 lung cancer cells. Also, a special focus was given to study the effect of CA in combination with the PS Zinc phthalocyanine in PDT.

2. Results

The morphological changes of treated and untreated A549 cells are displayed in Figure 2. Untreated control cells (a) showed no abnormal cellular morphological changes and maintained the shape of lung cancer cells. Treatment with different doses of CA (20, 40, 60, 80, 100 µM) demonstrated distinct morphological changes (round and detached non-viable cells floating in the culture media), inferring an increase in cell death with the increase in CA doses.

The results of trypan blue viability assay showed a dose-dependent reduction in cell viability significantly in lung cancer cells treated with increasing concentrations of CA (20, 40, 60 80, 100 µM)
when compared to untreated control cells (Figure 3). A 50% inhibition (IC₅₀) of cells was observed at 52 μM concentration of CA.

**Figure 2.** Morphological changes of A549 cells due to the result of CA treatment in different doses (40x magnification). Where, (a) are untreated cells; (b–f) are cells were treated with 20, 40, 60, 80, and 100 μM of CA, respectively. Morphological changes, including rounding of cells, detachment, floating cells in culture media, and brightly illuminated dead cells were observed in the images. It was clear that a steady increase in the aforesaid morphological changes identifying cancer cell death were noted in CA treated cells (b–f) with reference to untreated control cells revealing the dose-dependent cell growth inhibition of CA.

**Figure 3.** Effect of different doses of CA (20–100 μM) on the percentage cell viability of A549 lung cancer cells. Values presented as mean ± SE from independent duplicate experiments; n = 4. * p < 0.05, ** p < 0.01 and *** p < 0.001.
LDH leakage assay was used to assess the integrity of membranes determined through the estimation of LDH leaked in cell media due to the damaged membrane of cells, which in turn was measured at 490 nm. The cells which received CA at different doses (20–100 µM), significantly (p < 0.001) increased the cell membrane damage than the control cells (Figure 4). This reflected a dose-dependent increase in the cytotoxicity upon CA (20–100 µM) treatment. LDH levels measured are directly proportional to the cell’s damage.

Figure 4. Dose-dependent cytotoxic effect of CA on A549 lung cancer cells as measured by LDH leakage. The test samples showed increased cytotoxicity with an increase in doses when control compared to control samples. Significant dose-dependent cytotoxicity was observed in A549 cells treated with CA (20–100 µM). Values presented as mean ± SE from independent duplicate experiments; n = 4. * p < 0.05, ** p < 0.01 and *** p < 0.001.

The energy levels of the cells were measured by calculating the ATP levels of the cells. The energy levels in A549 cells were higher, as indicated by the elevated ATP levels in control cells (Figure 5). Cells that received different doses of CA (20–100 µM) established a significant decline in ATP luminescence as related to control and CA alone treated cells. The reduction in ATP luminescence indicates a reduction in cell proliferation by treatments.

Based on the above data obtained from the morphological analysis, cell viability, cytotoxicity, and cell proliferation, it is thus clear that CA expressed a linear dose-dependent cell growth inhibition with an increase in the doses (20–100 µM). The IC_{50} dose of CA (52 µM) was employed further in PDT experiments.

In the PDT experiments, the cell viability analysis by trypan blue showed that untreated control (group 1) cells did not show any loss of viability, which was slightly decreased in laser alone treated cells (group 2) (84.77%) (Table 1). The PDT group (group 3) showed a significant drop in viability (51.43%). Interestingly when CA (52 µM) was introduced in PDT, it significantly reduced the cell viability to 27.80%, indicating a pronounced cytotoxic effect due to the presence CA in group 4.

Similarly, in LDH leakage assay, the introduction of CA in PDT along with PS and laser presented a significant surge in cytotoxicity accompanied by cell membrane damage when referred to untreated, laser and PDT groups (Table 1).

The effect of CA on cell proliferation in PDT of A549 cells was displayed in Figure 6. The energy level of the untreated control cells was found to be higher when compared to treated groups. Laser treatment and PDT showed a substantial drop in cell proliferation and indicating the effectiveness of treatment.
Whereas, when CA was introduced in PDT, a further significant reduction of cell proliferation was noted when compared to PDT and control groups.
Table 1. Effect of CA in PDT on percentage cell viability and cytotoxicity of lung cancer cells.

| Groups   | Cell Viability (Trypan Blue) | Cytotoxicity (LDH Leakage) |
|----------|-----------------------------|-----------------------------|
|          | Percentage (%)              | Absorbance @490 nm          |
| Group 1  | 98.24 ± 0.84                | 0.08 ± 0.02                 |
| Group 2  | 84.77 ± 0.39 *              | 0.34 ± 0.01 *               |
| Group 3  | 51.43 ± 0.72 **             | 0.76 ± 0.14 **              |
| Group 4  | 27.80 ± 1.56 ***            | 1.53 ± 0.52 ***             |

Group 1 (Control), untreated cells; group 2, laser control (5 J/cm$^2$); group 3 (PDT), PS (15 µM) + laser (5 J/cm$^2$); group 4 (Phyto-PDT), CA (52 µM) + PS (15 µM) + laser (5 J/cm$^2$); Values presented as mean ± SE from independent duplicate experiments with statistical significance at; n = 4; * p < 0.05, ** p < 0.01 and *** p < 0.001.

Hoechst stain is a nuclear DNA specific blue stain permanently staining the DNA of the cells and hence it is used to evaluate the degree of DNA damage after the treatments. The Hoechst stain results (Figure 7) showed intact undisturbed dense oval nuclei indicating no or negligible DNA damage. Whereas on PDT and phyto-PDT treatments (combined treatment of CA with PS), the characteristic nuclear damage events such as nuclear shrinkage, nuclear retraction, and chromatic condensation were observed.

The arrow marks indicate the nuclear changes including cellular retraction, nuclear shrinkage and nuclear condensation which are characteristic signs of nuclear damage. The nuclear damage was increased in CA + PDT treatment when compared to PDT, laser alone, and control groups.

The CA-ZnPcSmix induced cell death was confirmed further by Annexin V-FITC/PI staining through flow cytometric analysis (Figure 8). In the untreated group (a), the viable cell count was 99.9%, with apoptotic and necrotic cell count relatively 0%. The percentages of live:apoptotic:dead cells in
laser alone treated group (b) was in the ratio of 52:47:0.1. Whereas in PDT (c) and CA-PDT (d) groups, it was found to be 43:50:6.1 and 26:63:10, respectively. The apoptotic cells percentage was enhanced in PDT and Phyto-PDT groups with reference to control groups.

Figure 8. Effects of CA and PDT on cell death of A549 cells by Annexin V-FITC/PI staining. Where, (a) group 1 (control), untreated cells; (b) group 2, laser control (5 J/cm²); (c) group 3 (PDT), PS (15 µM) + laser (5 J/cm²); (d) group 4 (Phyto-PDT), CA (52 µM) + PS (15 µM) + laser (5 J/cm²). CA-PDT treatment resulted in significantly increased number apoptotic and necrotic cells compared to PDT, irradiation alone and control cells.

3. Discussion

PDT is presently viewed as a promising treatment alternative to conventional cancer therapies for various cancers. In PDT, three individual non-toxic elements such as light, O₂, and PS cause damage to the cells and tissues when they are combined. The better results from PDT are based on the generation of ROS, O₂ yield, and molecular stability of the photosensitizing agent [18]. As the commercially synthesized PSs were accompanied with some degree of toxicities, plant-based PSs with low-level laser irradiations could offer a more promising area of cancer research. In recent years, phytochemicals are being increasingly recognized for potent complementary cancer treatments [19]. In the present study, the treatment of green tea CA in A549 cells showed a dose-dependent increase in the anticancer activity as assessed by the various biochemical assays. Also, it was observed that CA augmented the overall effect of PDT when treated together with the PS (Zinc phthalocyanine).
A decrease in cell viability in CA and PS treated cells observed in the present study, revealed the increased cytotoxicity due to the CA and PDT. CA induced cytotoxicity in cancer cells was previously reported in many experimental studies [20,21]. The oxidative stress in cancer cells was reported to cause membrane damage, which is a contributing factor for the cytotoxic effects observed in the present study. In PDT, the energy emitted from the excited PS was transferred to molecular O$_2$ to ROS, which is cytotoxic to the cells leading to cell death. As reported by previous works in our lab, increased oxidative stress by plant extracts and phytochemicals reduced the intracellular ATP levels [22]. Yang et al. reported that light-activated CA caused increased DNA strand breakage resulting in the depletion of cellular NAD$^+$ and ATP levels leading to cell death [23]. The nuclear damage observed in A549 cells by CA and PDT through Hoechst staining is in correlation with the observed morphological changes in the treated cells revealing cytotoxicity and cell death. Leo et al. reported the induction of nuclear damage by catechins in cancer cells [21]. The reduced ATP levels in CA and laser-treated cells (PDT groups) in the present study, is due to this reason.

Increased LDH levels leaked into the cell media, as observed in the present study in CA and ZnPcsSmix treated cells, is due to the disruption of the cell membrane by the treatment. Green tea polyphenols are known to induce cancer cell membrane damage resulting in the release of LDH [24].

The phototoxic effects of CA and PDT, as indicated by assay results of LDH cytotoxicity, ATP proliferation assays, and trypan blue cell viability, led the cells to death by triggering apoptotic signaling pathways. CAs were reported to influence the cancer signal transduction pathways leading to cell death [24]. In vivo and in vitro studies have confirmed the inhibition of carcinogenesis by CAs at initiation, promotion, and progression stages. This complicated obstruction of tumorigenesis is due to the combined pharmacological effects of CA [25].

The -OH bond of CA molecule in the heterocyclic ring was excited and oxidized by photosensitization, resulting in the formation of a quinone derivative, which increases oxidative stress in cancer cells. CA could utilize these mechanisms in PDT, which would result in cancer cell damage [26]. Previously, Yang et al. reported the cytotoxic action of CA through aerobic photo-oxidation upon irradiation with blue light [27]. Numerous research evidence refers to the health-promoting capability of CAs with reference to its antioxidant activity. However, like other polyphenols, CAs can also generate as well as scavenge free radicals based on multiple factors. By a controlled combination of both mechanisms based on the requirements of the cell, CA may exert their beneficial effects, particularly in the fight against diseases like cancer [10,20,28].

PDT exerts its therapeutic effect mainly by the production of ROS resulting in increased oxidative stress in cancer cells. It is reported that, in PDT, the entry of PS to normal cells is either restricted or highly reduced due to the increased tumor vasculature and permeability of cancer cell membrane compared to normal cells. Moreover, ROS generated during PDT is short-lived and is effective within a very narrow range of 20 nm, thereby reducing its effect on normal cells. Thus, normal cells are not affected during PDT, which increases its clinical applications [8,29]. At the same time, CAs were also found to be protective over normal cells. The structure-activity relationship of CA was observed in previous experiments in relation to the phenomenon of photoactivation and photosensitization. The flavan-3-ol structure of CA shows the presence of two benzene rings with strong electron absorption upon UV light irradiation. In alkali or neutral solutions, CA was found to be sensitive to blue light resulting in photo-induced electron transfer. Upon irradiation, CA produces O$_2$• coupled with photosensitized oxidation, which could be harmful to the cellular components. The singlet molecular oxygen could react directly with substrates, which in turn react with oxygen to produce free radicals resulting in cellular damage [30].

Previous studies have reported that CAs improved the anticancer effects in vitro, in vivo, and in clinical trials when combined with other chemotherapeutic drugs. The photodynamic activity of other forms of green tea CAs has already been stated in several cancer types [31–34]. When combined with the photosensitizer Radachlorin at concentrations 2.5–5 µg, tea CAs showed increased anticancer activity in vitro and in vivo [31]. In a recent study by Niu et al. (2020), oral administration of tea
CA to human volunteers during radiotherapy reduced the therapy-induced side-effects [35]. It was also reported that CAs synergistically combine with other chemical drugs by enhancing apoptosis in human lung cancer cells [36].

CA was previously reported to impede cell viability, proliferation, and induce apoptotic signals in a dose-responsive fashion in cancer cells [10]. The increased effect of CA on cell proliferation, membrane damage, nuclear DNA damage, and cytotoxicity in PDT, as evidenced in the present study, revealed its photoactivated cancer cell inhibitory effect. Hence, the results of the present study revealed the enhancement of overall Zn Phthalocyanine-PDT effects by CA, which confirms that this green tea flavonoid could have acted additively or synergistically when combined with a photosensitizer in the PDT of cancer. These findings instigate the possibility of introducing CA in phyto-photodynamic therapy of cancer in the future.

4. Materials and Methods

4.1. Chemicals and Reagents

(+)-Catechin (CA) was obtained from Sigma, Johannesburg, South Africa (PHR1963). Fetal bovine serum (FBS; Biochrom, S0615), Roswell Park Memorial Institute 1640 medium (RPMI), (Sigma, R8758), penicillin/streptomycin (Sigma, P4333), amphotericin B (Sigma, A2942), trypan blue (Sigma Aldrich, T8154), phosphate-buffered saline (PBS), Hank’s balanced salt solution (HBSS) (Invitrogen, 10–543 F), propidium iodide (PI) and TrypLE Express (Gibco, 12563-029, Thermo Fisher Scientific, Johannesburg, South Africa), were used for the present study.

4.2. Cell Culture

A549 lung cancer cells used in this study were purchased from ATCC (ATCC® CCL-185). A549 cells were maintained and cultured in RPMI medium complemented with 10% FBS, 0.5% penicillin/streptomycin, and 0.5% amphotericin B and incubated at 37 °C in 5% CO₂ and 85% humidity. When the cells in the culture dishes were 80% confluent, the spent media were discarded, cells washed twice with HBSS and detached with TrypLE Express at a ratio of 1 mL/25 cm². For the biochemical analysis, approximately 2 × 10⁵ cells were seeded in culture plates of diameter 3.4 cm² with 3 mL complete medium and incubated for 4 h to attach.

4.3. Dose-Response Analysis of CA

A stock solution of 1 M CA was prepared in distilled water and stored at 4 °C. Further dilutions were made in culture media to obtain the desired concentrations as per the experimental design. For dose-depndant analysis, A549 cells were administered with increasing doses of CA (20, 40, 60 80, and 100 µM) for 24 h.

4.4. PDT Experiment

For PDT experiments, Zinc (II) phthalocyanine (ZnPCSmix), which is an II-generation PS, having a maximum light penetration in tissues at absorption Q bands between 520–770 nm was used in the present study. ZnPCSmix has a triplet quantum yield of 0.53, singlet oxygen quantum yield (FΔ) of 0.45, triplet lifetime of 2.95 s, and fluorescence quantum yield of 0.16 with an absorption peak at 680 nm [22]. Briefly, the cells were separated into 4 groups (Table 2); group 1 control cells received no treatment and irradiation. Group 2 cells received laser irradiation only, served as laser control. Cells in group 3, were treated with PS (15 µM), and group 4 cells were treated with PS (15 µM) and CA (52 µM-IC₅₀ concentration). After 20 h of incubation (37 °C with 5% CO₂), the cells in groups 2–4 were irradiated in the dark with the lids off using a diode laser of emitting wavelength 680 nm (National Laser Centre, Pretoria, South Africa) at 5 J/cm² fluency [22]. The Laser parameters are summarized in Table 3. To avoid light interference from disturbing the PDT experiments, all the irradiations were done in
the dark. The cells were further incubated in the dark for 24 h after irradiation and used for various biochemical assays.

**Table 2.** Experimental design for the effect of CA in PDT of A549 cells.

| Groups                | Treatment Schedules                                      |
|-----------------------|----------------------------------------------------------|
| Group (Control)       | Untreated A549 cells (2 × 10^5 cells); 0 J/cm^2 Fluence |
| Group 2 (Laser control) | Cells received irradiation only (5 J/cm^2)               |
| Group 3 (PDT)         | Cells received PS (15 µM) and irradiation (5 J/cm^2)     |
| Group 4 (Phyto-PDT)   | Cells received CA (52 µM), PS (15 µM) and irradiation (5 J/cm^2) |

**Table 3.** Laser parameters employed in the present study.

| Parameters         | Values            |
|--------------------|-------------------|
| Laser type         | Semiconductor (diode) |
| Wavelength         | 680 nm            |
| Wave emission      | Continuous        |
| Fluence            | 5 J/cm^2          |
| Output power       | 200 mW/cm^2       |
| Irradiation time   | 3 min, 26 s       |
| Spot size          | 9.1 cm^2          |

4.5. **Morphological Cellular Analysis by Inverted Light Microscope**

The morphological changes in the cells were examined after 24 h post-treatment and recorded in the control and experimental groups using a camera attached inverted light microscope (CKX41, Olympus, Wirsam, Richmond, Johannesburg, South Africa) connected to the cellSens image analysis software. The harvested cells were resuspended in PBS or HBSS for further biochemical analysis.

4.6. **Cellular Viability Analysis by Trypan Blue Assay**

The cell viability was estimated using the trypan blue (Sigma-Aldrich T8154) dye exclusion test. The dye was taken in by the dead cells (appear blue) due to membrane damage by treatment drugs whereas the intact membrane in the live cells (appear white) will not allow the dye inside the cell. The live and viable cells selectively exclude the dye and this principle was employed for measuring cell viability. Equal amount (10 µL) of cell suspension and dye was mixed and added (in an aliquot of 10 µL) to a countess slide designed for Countess automated cell counter (Countess® Automated Cell Counter, ThermoFisher Scientific, Johannesburg, South Africa). The number of live, dead and total cells present was counted automatically by inserting the slide into the countess cell counter and the percentage cell viability was calculated.

4.7. **Cell Proliferation by ATP Luminescence Assay**

The measure of energy carrier molecule ATP released from the active cells was calculated by CellTiter-Glo® ATP luminescence assay kit (Promega, G7570, Anatech Analytical Technology, Bellville, South Africa). The cell proliferation is calculated based on the amount of metabolically active cells retained after treatment. Equal volumes of (50 µL) of ATP CellTiter-Glo® reagent cell suspension was added to an opaque-walled 96 well plate (BD Biosciences, 353,296, San Jose, CA, USA) and mixed in an orbital shaker for 10 min in the dark at room temperature (RT). The luminesce released was measured with media as background control through a Multilabel Counter (Perkin Elmer, VICTOR3™, 1420, Separation Scientific, Johannesburg, South Africa) in Relative Light Units (RLU).

4.8. **Membrane Integrity Assessment by Lactate Dehydrogenase (LDH) Assay**

The CytoTox96® Assay kit (Promega S.A. G4000, Whitehead Scientific, Johannesburg, South Africa) was used to measure the LDH released by treated and untreated cells. The enzyme LDH is present in
the cytosol of live cells that is released in the culture media due to membrane damage forming a red
formazan complex by reacting with the assay fluid, which was read at 490 nm. Hence, the measure of
LDH diffused in media gives the measure of membrane damage or cytotoxicity. Briefly, equal volumes
of (50 µL) substrate and spent media from each group were added, mixed, and incubated for 30 min in
the dark at RT for the formation of formazan complex, which was read using a Multilabel Counter.

4.9. Assessment of Nuclear Damage by Hoechst Stain

After 24 h of drug and PDT treatments to the cells grown in coverslip, they were washed twice
with PBS (pH 7.4), fixed with 4% paraformaldehyde, and stained with 10 mg/mL Hoechst stain
(Hoechst 33258, H21491, Invitrogen, ThermoFisher Scientific, South Africa) for 15 min. The stained
cells were washed with PBS (pH 7.4) and viewed for nuclear damage was viewed in Olympus BX41
fluorescent microscope, South Africa.

4.10. Analysis of Cell Death by Annexin V-PI Stain

The percentage of non-apoptotic and apoptotic cells in the control and treated groups through
flow cytometric analysis using Annexin V-fluorescein isothiocyanate (FITC) kit (Becton Dickinson,
556570, Scientific Group, Johannesburg, South Africa). Briefly, an aliquot of 100 µL (1 × 10⁶ cells/mL)
of cell suspension was washed twice with 1xPBS (pH 7.4), suspended in 1x binding buffer and stained
with Annexin V-FITC (5 µL) and PI (5 µL) for 15 min (dark) at RT. The population of live, apoptosis,
and necrotic cells were determined using Fluorescence-Activated Cell Sorting (FACS) Aria flow
cytometer (Becton Dickinson).

4.11. Statistical Analysis

Lung cancer cells from passages 16–20 were employed for the present study. All the experiments
were carried out at least 4 times (n = 4) and the results were statistically analyzed by SigmaPlot version
13 using the student’s paired t-test. Values are represented as mean± standard error (SE) at a statistical
significance of p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***)

5. Conclusions

Based on the previous literature, we found that the effect CA in PDT of A549 lung cancer cells
was not reported. The overall results of the study revealed that CA promoted cell death in lung cancer
cells in a dose-dependent manner, and it also offered better results in combination with PS in PDT.
The individual dose of the anticancer drug is one of the very important factors determining the efficiency
of cancer therapy. Reports suggest that CA synergistically combines with other anticancer compounds
and treatments. This leaves a chance for combining CA with ZnPcSmix as a novel treatment strategy
to improve PDT outcomes. This combination could also possibly reduce the optimum treatment doses
of the commercial photosensitizers, which in turn could reduce the dose-limiting side effects of PDT.
It should be important to note that since the tissue concentrations of these flavan-3-ols are in the
micromolar range, a targeted nano-drug delivery system with CA would offer many promising results
in cancer PDT in the near future.

Author Contributions: Conceptualization, methodology, formal analysis, writing—original draft preparation,
G.J.S.; Supervision, project administration, writing—review, and editing; B.P.G.; Supervision, project administration,
writing—review and editing, funding acquisition; H.A. All authors have read and agreed to the published version
of the manuscript.

Funding: This research was funded by the South African Research Chairs Initiative of the Department of Science
and Technology and National Research Foundation of South Africa, grant number 98337.

Acknowledgments: This work is based on the research supported by the South African Research Chairs
Initiative of the Department of Science and Technology and the National Research Foundation of South Africa
(Grant No. 98337). As well as grants received from the University of Johannesburg (URC), the National Research
Foundation (NRF), and the CSIR (Council for Scientific and industrial Research)—NLC (National Laser Centre)
Laser Rental Pool Programme.
Conflicts of Interest: The authors declare no conflict of interest.

References

1. WHO. International Agency for Research on Cancer; Press Release; WHO: Geneva, Switzerland, 2018. Available online: https://www.iarc.fr/ (accessed on 2 September 2020).
2. Mokwena, M.G.; Kruger, C.A.; Ivan, M.T.; Heidi, A. A review of nanoparticle photosensitizer drug delivery uptake systems for photodynamic treatment of lung cancer. Photodiagnosis Photodyn. Ther. 2018, 22, 147–154. [CrossRef] [PubMed]
3. Zhang, T.; Bao, J.; Zhang, M.; Ge, Y.; Wei, J.; Li, Y.; Wang, W.; Li, M.; Jin, Y. Chemo-photodynamic therapy by pulmonary delivery of gefitinib nanoparticles and 5-aminolevulinic acid for treatment of primary lung cancer of rats. Photodiagnosis Photodyn. Ther. 2020, 11, 101807. [CrossRef] [PubMed]
4. Ozog, D.M.; Rkein, A.M.; Fabi, S.G.; Gold, M.H.; Goldman, M.P.; Lowe, N.J.; Martin, G.M.; Munavalli, G.S. Photodynamic therapy: A clinical consensus guide. Dermatol. Surg. 2016, 42, 804–827. [CrossRef] [PubMed]
5. Baghdan, E.; Duse, L.; Schüer, J.J.; Pinnapireddy, S.R.; Pourasghar, M.; Schäfer, J.; Schneider, M.; Bakowsky, U. Development of inhalable curcumin loaded Nano-in-Microparticles for bronchoscopic photodynamic therapy. Eur. J. Pharm. Sci. 2019, 132, 63–71. [CrossRef]
6. Zhang, L.; Wang, J.; Zhang, Y.; Ke, L.; Lin, X.; Li, Z.; Chen, H.; Gao, Y. Indocyanine green-encapsulated erlotinib modified chitosan nanoparticles for targeted chemo-photodynamic therapy of lung cancer cells. Dye. Pigment. 2019, 170, 107588. [CrossRef]
7. Chen, Y.S.; Peng, Y.B.; Yao, M.; Teng, J.P.; Ni, D.; Zhu, Z.J.; Zhuang, B.F.; Yang, Z.Y. Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth. Biochem. Biophys. Res. Commun. 2017, 487, 567–572. [CrossRef]
8. Senapathy, G.J.; George, B.P.; Abrahamse, H. Exploring the Role of Phytochemicals as Potent Natural Photosensitizers in Photodynamic Therapy. Anti-Cancer Agents Med. Chem. 2020. [CrossRef]
9. Bernatoniene, J.; Kopustinskiene, D.M. The role of catechins in cellular responses to oxidative stress. Molecules 2018, 23, 965. [CrossRef]
10. Braicu, C.; Ladomery, M.R.; Chedea, V.S.; Inmie, A.; Berindan-Neagoe, I. The relationship between the structure and biological actions of green tea catechins. Food Chem. 2013, 141, 3282–3289. [CrossRef]
11. Al-Hazzani, A.A.; Alshatwi, A.A. Catechin hydrate inhibits proliferation and mediates apoptosis of SiHa human cervical cancer cells. Food Chem. Toxicol. 2011, 49, 3281–3286. [CrossRef]
12. Przystupski, D.; Michel, O.; Rosowska, J.; Kwiatkowski, S.; Saczko, J.; Kulbacka, J. The modulatory effect of green tea catechin on drug resistance in human ovarian cancer cells. Med. Chem. Res. 2019, 28, 657–667. [CrossRef]
13. Sharifi-Rad, M.; Pezzani, R.; Redaelli, M.; Zorzan, M.; Imran, M.; Ahmed Khalil, A.; Salehi, B.; Sharopov, F.; Cho, W.C.; Sharifi-Rad, J. Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer. Molecules 2020, 25, 467. [CrossRef] [PubMed]
14. Abotaleb, M.; Samuel, S.M.; Varghese, E.; Varghese, S.; Kubatka, P.; Liskova, A.; Büsselberg, D. Flavonoids in cancer and apoptosis. Cancers 2019, 11, 28. [CrossRef] [PubMed]
15. Kopustinskiene, D.M.; Jakstas, V.; Savickas, A.; Bernatoniene, J. Flavonoids as anticancer agents. Nutrients 2020, 12, 457. [CrossRef]
16. Anand, A.Z.; Subhash, L.B. Polyphenols in Chronic Diseases and their Mechanisms of Action. In Polyphenols in Human Health and Disease; Elsevier: Amsterdam, The Netherlands, 2014; Chapter 21; pp. 265–271.
17. Ezzat, H.M.; Elnagar, Y.S.; Abdallah, O.Y. Improved oral bioavailability of the anticancer drug catechin using chitosomes: Design, in-vitro appraisal and in-vivo studies. Int. J. Pharm. 2019, 565, 488–498. [CrossRef]
18. Zhang, J.; Jiang, C.; Longo, J.P.; Azevedo, R.B.; Zhang, H.; Muehlmann, L.A. An updated overview on the development of new photosensitizers for anticancer photodynamic therapy. Acta Pharm. Sin. B 2018, 8, 137–146. [CrossRef]
19. Siweert, B.; Stupnner, H. The photoactivity of natural products—An overlooked potential of phytomedicines? Phytomedicine 2019, 60, 152985. [CrossRef]
20. Di Leo, N.; Battaglini, M.; Berger, L.; Giannaccini, M.; Dente, L.; Hampel, S.; Vittorio, O.; Cirillo, G.; Raffa, V. A catechin nanoformulation inhibits WM266 melanoma cell proliferation, migration and associated neo-angiogenesis. Eur. J. Pharm. Biopharm. 2017, 114, 1–10. [CrossRef]
21. Tao, L.; Forester, S.C.; Lambert, J.D. The role of the mitochondrial oxidative stress in the cytotoxic effects of the green tea catechin, (−)-epigallocatechin-3-gallate, in oral cells. *Mol. Nutr. Food Res.* 2014, 58, 665–676. [CrossRef]

22. George, B.P.; Abrahamse, H.; Hemmaragala, N.M. Anticancer effects elicited by combination of Rubus extract with phthalocyanine photosensitiser on MCF-7 human breast cancer cells. *Photodiagnosis Photodyn. Ther.* 2017, 19, 266–273. [CrossRef]

23. Yang, M.J.; Hung, Y.A.; Wong, T.W.; Lee, N.Y.; Yuann, J.M.; Huang, S.T.; Wu, C.Y.; Chen, I.Z.; Liang, J.Y. Effects of blue-light-induced free radical formation from catechin hydrate on the inactivation of Acinetobacter baumannii, including a carbapenem-resistant strain. *Molecules* 2018, 23, 1631. [CrossRef][PubMed]

24. Yamauchi, R.; Sasaki, K.; Yoshida, K. Identification of epigallocatechin-3-gallate in green tea polyphenols as a potent inducer of p53-dependent apoptosis in the human lung cancer cell line A549. *Toxicol. Vitro* 2009, 23, 834–839. [CrossRef][PubMed]

25. Zaveri, N.T. Green tea and its polyphenolic catechins: Medicinal uses in cancer and noncancer applications. *Life Sci.* 2006, 78, 2073–2080. [CrossRef][PubMed]

26. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. *Int. J. Biochem. Cell Biol.* 2007, 39, 44–84. [CrossRef]

27. Yang, M.Y.; Chang, K.C.; Chen, L.Y.; Wang, P.C.; Chou, C.C.; Wu, Z.B.; Hu, A. Blue light irradiation triggers the antimicrobial potential of ZnO nanoparticles on drug-resistant *Acinetobacter baumannii*. *J. Photochem. Photobiol. B Biol.* 2018, 180, 235–242. [CrossRef]

28. Chedea, V.S.; Braicu, C.; Socaciu, C. Antioxidant/prooxidant activity of a polyphenolic grape seed extract. *Food Chem.* 2010, 121, 132–139. [CrossRef]

29. Chizenga, E.P.; Abrahamse, H. Nanotechnology in Modern Photodynamic Therapy of Cancer: A Review of Cellular Resistance Patterns Affecting the Therapeutic Response. *Pharmaceutics* 2020, 12, 632. [CrossRef]

30. Liang, J.Y.; Wu, J.Y.; Yang, M.Y.; Hu, A.; Chen, L.Y. Photo-catalytic polymerization of catechin molecules in alkaline aqueous. *J. Photochem. Photobiol. B Biol.* 2016, 165, 115–120. [CrossRef][PubMed]

31. Mun, S.T.; Bae, D.H.; Ahn, W.S. Epigallocatechin gallate with photodynamic therapy enhances anti-tumor effects in vivo and in vitro. *Photodiagnosis Photodyn. Ther.* 2014, 11, 141–147. [CrossRef]

32. Ferrario, A.; Luna, M.; Rucker, N.; Wong, S.; Gomer, C.J. Pro-apoptotic and anti-inflammatory properties of the green tea constituent epigallocatechin gallate increase photodynamic therapy responsiveness. *Lasers Surg. Med.* 2011, 43, 644–650. [CrossRef]

33. Raish, M.; Husain, S.Z.; Bae, S.M.; Han, S.J.; Park, C.H.; Shin, J.C.; Ahn, W.S. Photodynamic therapy in combination with green tea polyphenol EGCG enhances antitumor efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells. *Prevention* 2010, 19, 24.

34. Qi, H.; Abe, N.; Zhu, B.; Murata, Y.; Nakamura, Y. (−)-Epigallocatechin-3-Gallate Ameliorates Photodynamic Therapy Responses in an In Vitro T Lymphocyte Model. *Phytother. Res.* 2014, 28, 1486–1491. [CrossRef][PubMed]

35. Niu, X.; Zhao, H.; Zhu, W.; Zhao, Y.; Cao, X.; Xing, L. Efficacy of oral epigallocatechin-3-gallate solution administration during radiotherapy for non-small-cell lung cancer patients: A long-term observational study. *Radiat. Med. Prot.* 2020, 1, 94–98. [CrossRef]

36. Oya, Y.; Mondal, A.; Rawangkan, A.; Umumarg, S.; Iida, K.; Watanabe, T.; Kanno, M.; Suzuki, K.; Li, Z.; Kagechika, H.; et al. Down-regulation of histone deacetylase 4, −5 and −6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin. *J. Nutr. Biochem.* 2017, 42, 7–16. [CrossRef][PubMed]

**Sample Availability:** Samples of the compounds are not available from the authors.

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).